Small-Cap Catalyst Pharmaceuticals Is Among Market’s Best Price Performers

Published by
ValueWalk

Small-cap biotech Catalyst Pharmaceuticals recently joined the S&P 600 index, which means institutions must own shares to track the indexThe company has a steady history of price appreciation going back one year, even while the broad market declinedCatalyst has been outpacing the S&P 600 index by a wide marginThe company’s earnings and revenue growth accelerated in the past three quarters, and analysts see double-digit top- and bottom-line growth aheadQ2 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a f…

Read More

See also  Airbnb lays off employees due to travel decline

Leave a Reply